The synthetic lethality of PARP14 inhibitors along with an identified genetic defect in the DNA repair process would make PARP14 a remarkable target for chemosensitizer design, which means the combination of PARP14 inhibitors and anticancer drugs causing DNA damage activity can amplify the cancer cell killing effect. Here, PARP14 is linked to cancer.